Peptomyc
Manuela Dr. med Niewel has a wealth of experience in the pharmaceutical industry, with a focus on clinical development and oncology. Manuela is currently serving as the Chief Medical Officer at Peptomyc since October 2019. Prior to that, they worked as a Medical Consultant Clinical Development at T-knife, Immunicum AB, and MonTa Biosciences from January 2019 to October 2019. Manuela also held the position of Senior Vice President Clinical Development at Rigontec GmbH from 2015 until 2018. Before joining Rigontec, they worked as the Medical Director, Oncology at Chiltern from 2013 to 2015. From 2003 to 2012, they served as the Senior Medical Director Oncology, Europe and ROW at PharmaNet/i3. Manuela's career started in 1998 when they held the role of Chief Scientific Officer at Oncology Services GMBH.
Manuela Dr. med Niewel obtained a degree in Medicine from the Technical University of Munich in 1988. Manuela holds the title of Dr. med. during this time. Additionally, they hold a Diploma of Pharmaceutical Medicine from DGPharMed, although the start and end years for this qualification are not provided.
This person is not in any teams
This person is not in any offices
Peptomyc
Peptomyc is a company focused on the development of a new generation of cell-penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment. The company was founded in December 2014 and it is based on Dr. Soucek’s scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years.Currently,cancer incidence in the world exceeds 14 million cases per year and results in 8 million deaths annually. Moreover, such numbers are forecast to rise by 75% over the next 20 years (World Cancer Report. International Agency for Research on Cancer 2014). At the moment, standard therapies include surgery, radiotherapy, chemotherapy, and, in a restricted subset of cancers, precision medicine. Unfortunately, very often these therapies fail, due to the development of resistance.Peptomyc has adopted a different strategy based on the inhibition of the oncoprotein Myc, which is found deregulated in the majority of human cancers. Myc holds a non-redundant function in cancer around which tumors cannot evolve, hence targeting Myc is the most promising therapeutic opportunity to date. Although Myc plays a central role in cancer there is currently no Myc inhibitor in the market.